Table 6 Study outcomes by treatment group
Study endpoint | Treatment X N = XXX n (%) | Treatment Y N = XXX n (%) | Hazard ratio (95% CI) | p value |
|---|---|---|---|---|
Primary outcome | ||||
Any surgical site infection | ||||
Superficial incisional | ||||
Deep incisional | ||||
Organ/space | ||||
Secondary outcomes | ||||
Any antibiotic-related complication | ||||
Stomach cramps | ||||
Nausea/vomiting | ||||
Oral candidiasis | ||||
Unusual bleeding/bruising | ||||
Difficulty breathing | ||||
Sore mouth/throat | ||||
Allergic reaction (itching, drug fever, skin rash, anaphylaxis) | ||||
Anemia/low blood counts | ||||
Skin reaction | ||||
Diarrhea | ||||
Liver toxicity | ||||
Kidney toxicity | ||||
Clostridioides difficile-associated colitis | ||||
Toxic megacolon | ||||
Opportunistic fungal infection | ||||
Indwelling catheter-related sepsis | ||||
Other antibiotic-related events | ||||
Any unplanned re-operation | ||||
Implant revision | ||||
Irrigation and debridement | ||||
Wound flap | ||||
Skin graft | ||||
Bone graft | ||||
Implant exchange | ||||
Extensor mechanism reconstruction | ||||
Repeat tumor excision | ||||
Antibiotic spacer insertion | ||||
Patellar reconstruction | ||||
Abductor reconstruction | ||||
Rotationplasty | ||||
Amputation | ||||
Other unplanned re-operations | ||||
Any oncologic event | ||||
Local recurrence | ||||
Distant metastases | ||||
Mortality due to any cause | ||||
Mortality due to disease progression | ||||